The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1178
March 15, 2004
View Complete Issue         Table of Contents 2019 
Abarelix (Plenaxis) for Advanced Prostate Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Abarelix (Plenaxis) for Advanced Prostate Cancer
March 15, 2004 (Issue: 1178)
Abarelix (Plenaxis - Praecis Pharmaceuticals), an injectable gonadotropin-releasing hormone (GnRH) antagonist, has been approved by the FDA for treatment of advanced symptomatic prostate cancer in patients who should not take luteinizing...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Abarelix (Plenaxis) for Advanced Prostate Cancer
Article code: 1178b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.